ArticleFrontiers in pharmacology2020
Clinical Efficacy Evaluation of 1-Year Subcutaneous Immunotherapy for
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Roles of Metabolomics in Allergic Rhinitis: From Cell to Bedside Investigations.International journal of molecular sciences · 2026Review
- The GATA3-STEAP4 Axis Drives Inflammation by Promoting Th2 Differentiation in Allergic Rhinitis.Inflammation · 2025Article
- Multi-omics in Allergic Rhinitis: Mechanism Dissection and Precision Medicine.Clinical reviews in allergy & immunology · 2025Review
- Article
- Green carbon dots derived fromFrontiers in immunology · 2024Article
- Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation.Journal of personalized medicine · 2023Review
- Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update.Allergy, asthma & immunology research · 2022Review
- Biomarkers of AIT: Models of prediction of efficacy.Allergologie select · 2022Review
- Circulating MIF Associated With Disease Severity and Clinical Response of Sublingual Immunotherapy in House Dust Mite-Induced Allergic Rhinitis.Frontiers in pharmacology · 2021Article
- Metabolomics reveals sex-specific metabolic shifts and predicts the duration from positive to negative in non-severe COVID-19 patients during recovery process.Computational and structural biotechnology journal · 2021Article
- Leukotriene AFrontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous immunotherapy is the only treatment that improves the natural progression of allergic rhinitis and maintains long-term outcomes after discontinuation of the drug. Metabolomics is increasingly applied in the study of allergic diseases, including allergic rhinitis. However, little is known about the discovery of metabolites that can evaluate clinical efficacy and possible mechanisms of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.